US FDA approves Byetta for first-line monotherapy use
This article was originally published in Scrip
Executive Summary
The US FDA has approved Amylin/Lilly's injectable drug Byetta (exenatide) as a first-line monotherapy treatment for type 2 diabetes. The drug was previously approved for patients who were taking other antidiabetics, such as metformin or a sulfonylurea, but had not achieved adequate glycaemic control.